180 related articles for article (PubMed ID: 25637603)
1. Delineation of a conserved arrestin-biased signaling repertoire in vivo.
Maudsley S; Martin B; Gesty-Palmer D; Cheung H; Johnson C; Patel S; Becker KG; Wood WH; Zhang Y; Lehrmann E; Luttrell LM
Mol Pharmacol; 2015 Apr; 87(4):706-17. PubMed ID: 25637603
[TBL] [Abstract][Full Text] [Related]
2. Informatic deconvolution of biased GPCR signaling mechanisms from in vivo pharmacological experimentation.
Maudsley S; Martin B; Janssens J; Etienne H; Jushaj A; van Gastel J; Willemsen A; Chen H; Gesty-Palmer D; Luttrell LM
Methods; 2016 Jan; 92():51-63. PubMed ID: 25986936
[TBL] [Abstract][Full Text] [Related]
3. β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo.
Gesty-Palmer D; Yuan L; Martin B; Wood WH; Lee MH; Janech MG; Tsoi LC; Zheng WJ; Luttrell LM; Maudsley S
Mol Endocrinol; 2013 Feb; 27(2):296-314. PubMed ID: 23315939
[TBL] [Abstract][Full Text] [Related]
4. β-Arrestin-biased signaling of PTH analogs of the type 1 parathyroid hormone receptor.
van der Lee MM; Verkaar F; Wat JW; van Offenbeek J; Timmerman M; Voorneveld L; van Lith LH; Zaman GJ
Cell Signal; 2013 Feb; 25(2):527-38. PubMed ID: 23159578
[TBL] [Abstract][Full Text] [Related]
5. Biased agonism at the parathyroid hormone receptor: a demonstration of functional selectivity in bone metabolism.
Bohinc BN; Gesty-Palmer D
Mini Rev Med Chem; 2012 Aug; 12(9):856-65. PubMed ID: 22681253
[TBL] [Abstract][Full Text] [Related]
6. Translating in vitro ligand bias into in vivo efficacy.
Luttrell LM; Maudsley S; Gesty-Palmer D
Cell Signal; 2018 Jan; 41():46-55. PubMed ID: 28495495
[TBL] [Abstract][Full Text] [Related]
7. Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity.
Appleton KM; Lee MH; Alele C; Alele C; Luttrell DK; Peterson YK; Morinelli TA; Luttrell LM
Methods Enzymol; 2013; 522():229-62. PubMed ID: 23374189
[TBL] [Abstract][Full Text] [Related]
8. β-arrestin-biased agonism at the parathyroid hormone receptor uncouples bone formation from bone resorption.
Bohinc BN; Gesty-Palmer D
Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):112-9. PubMed ID: 21476967
[TBL] [Abstract][Full Text] [Related]
9. A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation.
Gesty-Palmer D; Flannery P; Yuan L; Corsino L; Spurney R; Lefkowitz RJ; Luttrell LM
Sci Transl Med; 2009 Oct; 1(1):1ra1. PubMed ID: 20368153
[TBL] [Abstract][Full Text] [Related]
10. Arrestins in bone.
Bohinc BN; Gesty-Palmer D
Prog Mol Biol Transl Sci; 2013; 118():335-58. PubMed ID: 23764060
[TBL] [Abstract][Full Text] [Related]
11. Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways.
Cupp ME; Nayak SK; Adem AS; Thomsen WJ
J Pharmacol Exp Ther; 2013 Jun; 345(3):404-18. PubMed ID: 23516330
[TBL] [Abstract][Full Text] [Related]
12. Beta-arrestin-dependent parathyroid hormone-stimulated extracellular signal-regulated kinase activation and parathyroid hormone type 1 receptor internalization.
Sneddon WB; Friedman PA
Endocrinology; 2007 Aug; 148(8):4073-9. PubMed ID: 17525124
[TBL] [Abstract][Full Text] [Related]
13. Emergent biological properties of arrestin pathway-selective biased agonism.
Appleton KM; Luttrell LM
J Recept Signal Transduct Res; 2013 Jun; 33(3):153-61. PubMed ID: 23448506
[TBL] [Abstract][Full Text] [Related]
14. Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis.
Polyzos SA; Makras P; Efstathiadou Z; Anastasilakis AD
Expert Opin Investig Drugs; 2015 Feb; 24(2):145-57. PubMed ID: 25316089
[TBL] [Abstract][Full Text] [Related]
15. 'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass?
Gesty-Palmer D; Luttrell LM
Br J Pharmacol; 2011 Sep; 164(1):59-67. PubMed ID: 21506957
[TBL] [Abstract][Full Text] [Related]
16. Beta-arrestin-biased parathyroid hormone ligands: a new approach to the development of agents that stimulate bone formation.
Ferrari SL; Bouxsein ML
Sci Transl Med; 2009 Oct; 1(1):1ps1. PubMed ID: 20368152
[TBL] [Abstract][Full Text] [Related]
17. Regulated expression of G protein-coupled receptor kinases (GRK's) and beta-arrestins in osteoblasts.
Spurney RF
Calcif Tissue Int; 2003 Aug; 73(2):153-60. PubMed ID: 14565597
[TBL] [Abstract][Full Text] [Related]
18. Arrestin pathways as drug targets.
Luttrell LM
Prog Mol Biol Transl Sci; 2013; 118():469-97. PubMed ID: 23764065
[TBL] [Abstract][Full Text] [Related]
19. β-Arrestin-biased signaling mediates memory reconsolidation.
Liu X; Ma L; Li HH; Huang B; Li YX; Tao YZ; Ma L
Proc Natl Acad Sci U S A; 2015 Apr; 112(14):4483-8. PubMed ID: 25831532
[TBL] [Abstract][Full Text] [Related]
20. Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.
Luttrell LM; Maudsley S; Bohn LM
Mol Pharmacol; 2015 Sep; 88(3):579-88. PubMed ID: 26134495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
